Nebenwirkungen · Aprovel
Aprovel 300 mg tablets. · Abschnitt 4.8 · PDF-Seite 34
HOS-087081 · Präparat HOS-083419
Very common: Hyperkalaemia* occurred more often in diabetic patients treated with irbesartan than with placebo. In diabetic hypertensive patients with microalbuminuria and normal renal function, hyperkalaemia (≥ 5.5 mEq/L) occurred in 29.4% of the patients in the irbesartan 300 mg group and 22% of the patients in the placebo group. In diabetic hypertensive patients with chronic renal insufficiency and overt proteinuria, hyperkalaemia (≥ 5.5 mEq/L) occurred in 46.3% of the patients in the irbesartan group and 26.3% of the patients in the placebo group. Common: significant increases in plasma creatine kinase were commonly observed (1.7%) in irbesartan treated subjects. None of these increases were associated with identifiable
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T10:05:00Z · SHA-256 9a7fe6a40dc5304cc03e5692e73b5a8b0895fbc3156dd4f3a748f38e97336ae6 · Passage 4ae9d946f08163cc026e09655726f22cd4b1e6795417a62c917376e2316ac795 · Zeichen 3273–4102 im Abschnitt